## Cholesterol *seco*-Sterol-Induced Aggregation of Methylated Amyloid-β Peptides—Insights into Aldehyde-Initiated Fibrillization of Amyloid-β\*\*

Johanna C. Scheinost, Hong Wang, Grant E. Boldt, John Offer, and Paul Wentworth, Jr.\*

The nucleation and aggregation of amyloid- $\beta$  (A $\beta$ ) peptides, A $\beta$ (1–40) and A $\beta$ (1–42), into neurotoxic oligomers is considered a primary event in Alzheimer's disease (AD) pathogenesis.<sup>[1,2]</sup> The vast majority of this disease is sporadic in origin (> 85 %),<sup>[3]</sup> involving the oligomerization of native A $\beta$ peptide oligomers, therefore, research is ongoing to classify the in vivo environmental triggers of AD onset that facilitate intracellular and extracellular nucleation, aggregation and deposition of native A $\beta$  peptide.

As part of our ongoing research in this area,<sup>[4]</sup> we discovered cholesterol seco-sterol aldehyde 1 (termed atheronal-B) in vivo.<sup>[5]</sup> Aldehyde 1 is quantifiable in all human plasma and central nervous system (CNS), but is significantly elevated in the plasma and inflamed arteries of patients with advanced atherosclerosis, and in the CNS of patients with inflammatory neurological disease.<sup>[5,6]</sup> We have further shown that adduction of 1 to apoB-100, a protein component of lowdensity lipoprotein (LDL), causes this protein to misfold in vitro,<sup>[5]</sup> a misfolding process that renders LDL particles susceptible for uptake into macrophages.<sup>[7]</sup> In addition, we have shown that **1** accelerates the aggregation of  $A\beta(1-40)$ and A $\beta$ (1–42) in vitro<sup>[8]</sup> hinting that **1** could be a plausible chemical factor linking the known AD association with atherosclerosis.<sup>[9]</sup> An important and largely unanswered question regarding lipid aldehyde-induced protein misfolding is the nature of the interaction between the aldehyde and the protein and how this facilitates protein aggregation.<sup>[4]</sup> Herein we show, by kinetic analyses of the atheronal-B (1)-induced oligomerization and fibrillization of a panel of synthetic mono-, bis- and tris-N,N-dimethylamine-containing A $\beta$ (1–40) protein sequences **2b-f** (Figure 1b), that the aggregation of

[*] J. C. Scheinost, Dr. G. E. Boldt, Dr. J. Offer, Prof. P. Wentworth, Jr.
The Scripps-Oxford Laboratory
Dept. of Biochemistry, University of Oxford
South Parks Rd., Oxford OX1 3QU (UK)
Fax: (+44) 1865-285-329
E-mail: paul.wentworth@bioch.ox.ac.uk
Homepage: http://www2.bioch.ox.ac.uk/wentworthlab
Dr. H. Wang, Prof. P. Wentworth, Jr.
Department of Chemistry and The Skaggs Institute for Chemical
Biology, The Scripps Research Institute
10550 N. Torrey Pines Rd., La Jolla CA 92037 (USA)

- [\*\*] This work was supported by a grant from The Scripps Research Institute. The authors thank R. P. Troseth (TSRI) for synthesis of 1, Dr. M. Wood for EM images, and Dr. P. R. Antrobus (UO) for high resolution ES-MS of peptides 2a-f.
  - Supporting information for this article is available on the WWW under http://www.angewandte.org or from the author.



**Figure 1.** Atheronal-B(1)-induced aggregation of A $\beta$ (1–40) peptide (**2a**). a) Schiff-base equilibrium between Lys 16 of A $\beta$ (1–40) (**2a**) and aldehyde **1**. Similar equilibria exist for Schiff-base formation at the  $\varepsilon$ amino group of Lys 28 and the  $\alpha$ -amino group of Asp 1. b) Amino acid sequences of A $\beta$ (1–40) (**2a**) and N,N-dimethylamino-containing peptide sequences (**2b–f**) synthesized for these studies. The central hydrophobic cluster (CHC) of A $\beta$  is underlined. K\* = N<sup>e</sup>,N<sup>e</sup>-dimethyl Lys.

A $\beta$ (1–40) peptide **2a** is accelerated by **1** only when the aldehyde adducts to the  $\varepsilon$ -amino group of Lys16; no initiation in oligomerization of **2a** is observed when aldehyde **1** adducts to either the  $\varepsilon$ -amino group of Lys28 or the  $\alpha$ -amino group amine of Asp1. In addition, the atheronal-B-induced aggregation of peptide A $\beta$ (1–40) **2a** is inhibited by cholesterol. Both data combine to suggest that the atheronal-B-induced aggregation of A $\beta$ (1–40) involves a high degree of structural recognition between the lipid and the peptide that involves, in part, binding of **1** into the putative cholesterol-binding domain of **2a**.

Atheronal-B (1) was synthesized as outlined previously.<sup>[5]</sup> Peptides **2a–f** were synthesized by Boc/benzyl solid phase peptide synthesis (SPPS) using in situ neutralization.<sup>[10]</sup>  $N^{e}$ , $N^{e}$ -Dimethyl Lys (**K**\*) substitutions were incorporated using Boc-Lys(Me)<sub>2</sub>-CO<sub>2</sub>H. The  $N^{\alpha}$ , $N^{\alpha}$ -dimethyl Asp group required for peptides **2d** and **2f** was incorporated using Me<sub>2</sub>N-Asp(OcHx)-CO<sub>2</sub>H, prepared by reductive amination



## Communications

of  $H_2N$ -Asp(OcHx)-CO<sub>2</sub>H (for full synthetic details see the Supporting Information).

The A $\beta$ (1–40) peptide analogs (**2b**–**f**, Figure 1 b) incorporate tertiary amines that replace the primary amines present in native A $\beta$ (1–40) (**2a**) at specific loci along the peptide chain. Tertiary amines are unable to form Schiff-base adducts with aldehydes, and are isoelectronic with primary amines at physiological pH (7.4), rendering them ideal for a study to elucidate putative site-specific modification of peptide primary amines by aldehydes. However, *N*,*N*-dimethylation of primary amine-containing peptides may lead to increased basicity and hydrophobicity of the resulting peptide,<sup>[11]</sup> coupled with an impaired ability to form H-bonds. Therefore, the impact of the non-isostructural *N*,*N*-dimethylamino modifications on oligomerization and fibrillization propensity of peptides **2b–f** was determined using a combination of TEM (Figure 2 and Figure S2 in the Supporting Information) and



Figure 2. Representative TEM images of fibrils of N,N-dimethylated amyloid- $\beta$  peptides: a) **2b** (K\*16), b) **2c** (K\*28), and c) **2f** (Me<sub>2</sub>N-D1, K\*16, K\*28).

thioflavin-T fluorescence (Figure S3). Fibrillization of the methylated A $\beta$  peptide analogs **2b–f** (100  $\mu$ M) was induced by incubation with shaking in phosphate buffered saline (PBS) (pH 7.4) containing NaN<sub>3</sub> (0.02 % w/v) at 37 °C. TEM analysis of the protein aggregates revealed that the methylated A $\beta$  analogues (**2b–f**) form a classical network of non-branched fibrillar aggregates, several micrometer in length, indistinguishable from native A $\beta$ (1–40) peptide **2a** (Figure 2 and Figure S2 in the Supporting Information).

A comparison of the kinetic profile of aggregation of the methylated peptides  $2\mathbf{b}$ -**f** relative to native  $2\mathbf{a}$  was determined from a timecourse of thioflavin T (ThT) fluorescence of a deseeded peptide solution (100 µM) in sodium acetate buffer (20 mM, pH 5.0) and NaCl (100 mM) by incubating with standing at 37 °C (see Supporting Information for experimental details).<sup>[12]</sup> This analysis revealed that the methylated peptides  $2\mathbf{b}$ -**f** have a classical sigmoidal aggregation profile, indicative of a nucleation-dependent polymerization process,<sup>[13,14]</sup> with all the peptides having a lag phase similar in duration to that observed with native  $2\mathbf{a}$ , about 1 h (Figure S3 in the Supporting Information).

Timecourses of ThT binding and fluorescence of peptides **2a–f** (100  $\mu$ M) in the presence or absence of atheronal-B (100  $\mu$ M) were then measured (Figure 3a–f) using a modification of our previous method.<sup>[8]</sup> In brief, peptides **2a–f** were deseeded in hexafluoroisopropanol (HFIP),<sup>[15]</sup> dissolved in dimethylsulfoxide (DMSO) and added into buffer (PBS, pH 7.4). The aggregation was initiated by addition of aldehyde **1** in isopropyl alcohol (IPA) and then proceeded quiescently at 37 °C. Aliquots were removed periodically, added to a ThT solution and the fluorescence of the ThT solution was measured. The concentration of peptide **2a–f** (100  $\mu$ M) was selected such that no measurable oligomerization of protein in the absence of **1** would occur (Figure 3a–f).

Incubation of atheronal-B (1) with peptide **2a** leads to rapid formation of ThT-positive aggregates (time to half maximal fluorescence,  $t_{50} = 14$  h, Figure 3 a) in a process that is thermodynamically favoured from the outset,<sup>[8,16]</sup> a socalled "downhill polymerization", that has no measurable lag phase (Figure 3 a).<sup>[17]</sup> Aldehyde **1** also generates ThT-positive aggregates when incubated with the *N*,*N*-dimethylated peptides **2c** (K\*28,  $t_{50} = 25$  h, Figure 3 c) and **2d** (Me<sub>2</sub>N-D1,  $t_{50} =$ 13 h, Figure 3 d) in a manner similar to that of **2a**; thus, the ThT profile in each case has no lag phase, with oligomerization proceeding immediately. In contrast, aldehyde **1** does not initiate the formation of ThT-positive aggregates when incubated with *N*,*N*-dimethylated peptides **2b** (K\*16, Figure 3b), **2e** (K\*16, K\*28, Figure 3e) and **2f** (Me<sub>2</sub>N-D1, K\*16, K\*28, Figure 3 f).



*Figure 3.* Kinetics of atheronal-B-induced aggregation of amyloid- $\beta$  peptides 2a–f. a–f) ThT analyses, ex: 440 nm and em: 485 nm reported as mean  $\pm$  SD. g–l) Far-UV CD analyses; mean residue ellipticity [ $\Theta$ ] at 217 nm reported as average of three scans of peptides 2a (—, wild-type); 2b (—, K\*16); 2c (—, K\*28); 2d (—, Me<sub>2</sub>N-D1); 2e (—, K\*16, K\*28); 2f (—, Me<sub>2</sub>N-D1, K\*16, K\*28). In each case, the peptide (100 µm) is incubated quiescently in the presence ( $\blacksquare$ ) or absence ( $\square$ ) of aldehdye 1 (100 µm) at 37°C.

3920 www.angewandte.org

© 2008 Wiley-VCH Verlag GmbH & Co. KGaA, Weinheim

We next investigated the secondary structure characteristics during atheronal-B-induced fibrillization of peptides 2a-f spectroscopically using far-UV circular dichroism (CD). For the CD analyses, the deseeding protocol was modified from that used in the ThT assay to remove the DMSO cosolvent. Thus, a typical aggregation involved deseeding in urea (8м) and glycine/NaOH (10 mм, pH 10). This stock solution was then diluted into PBS (final pH 7.4) containing  $NaN_3$  (0.02 % w/v) in the presence or absence of 1 (100 µm) in IPA (0.5% v/v) and the aggregation mixtures were then incubated quiescently at 37 °C. Fibrillization was followed by the time-dependent change in the mean residue ellipticity  $[\Theta]$ at 217 nm (the wavelength minimum for  $\beta$ -strand) (Figure 3). All the peptides **2a-f** were random coil (RC) at t=0(Figure 3g-l) and in the absence of 1, all the peptides remained in this form until ca. day 6 when the  $RC \rightarrow \beta$ strand transition started to occur; the classic conformational change that occurs during fibrillization of Aß peptides (for full CD spectra see Figure S5).<sup>[18]</sup>

For all peptides **2a–f**, the amount of  $\beta$ -strand increases from day 6 until the plateau phase is reached by ca. day 12. The time to half maximal [ $\Theta$ ] at 217 nm,  $t_{50}\Theta$ , for all the peptides was very similar, ranging from 8–10 d.

The kinetics of the far-UV CD of peptides **2a–f** in the presence of **1** supported the ThT fluorescence data (Figure 3 g–l). Specifically, atheronal-B accelerates the onset of  $\beta$ -strand formation when incubated with peptides **2a** [ $t_{50}\Theta = 5.5 \text{ d}$ , (8.0 d in the absence of **1**), Figure 3 g], **2c** [**K**\*28,  $t_{50}\Theta = 6.0 \text{ d}$  (9.5 d), Figure 3 i] and **2d** [**Me<sub>2</sub>N-D1**,  $t_{50}\Theta = 4.0 \text{ d}$  (9.0 d), Figure 3 j]. In contrast, atheronal-B has no effect on the onset of  $\beta$ -strand formation of peptides, **2b** [**K**\*16,  $t_{50}\Theta = 9 \text{ d}$  (9 d), Figure 3 h], **2e** [**K**\*16, **K**\*28,  $t_{50}\Theta = 9 \text{ d}$  (9 d), Figure 3 h], **2e** [**K**\*16, **K**\*28,  $t_{50}\Theta = 7.5 \text{ d}$  (8 d), Figure 3 l].

During the CD analyses, the atheronal-induced aggregation of 2a, 2c, and 2d proceeds with a measurable lag phase, indicative of a nucleated polymerization process (Figure 3g, i, and j). This observation is in contrast to the ThT fluorescence kinetic data, where ThT-positive aggregates start to form immediately (Figure 3a, c, and d). In our previous reports of lipid aldehyde **1** induced A $\beta$ (1–40) fibrillization, quiescent aggregation protocols, such as those used throughout this study, lead to a downhill polymerization with no lag phase.<sup>[8,16]</sup> AFM analysis has revealed that quiescent aggregation  $A\beta(1-$ 40) with **1** yields spherical aggregates, not fibrils.<sup>[8]</sup> However, if agitation is applied during the incubation of atheronal 1 with  $A\beta(1-40)$  (2a), fibrils are formed in a two stage process that does proceed through a nucleation process that has a measurable lag phase.<sup>[16]</sup> To help answer the quandary as to why with quiescent aggregation conditions we observe a lag phase in the atheronal-induced aggregation of 2a, we repeated the ThT fluorescence analysis of the aggregation of 2a (100 µM) in the presence and absence of 1 (100 µM), but using the deseeding method and buffer conditions employed for the CD assay. This approach led to a profile of aldehydeinduced ThT-positive aggregate generation indicative of a nucleation polymerization with a measurable lag phase (see Figure S4 in the Supporting Information). Clearly, the process by which atheronal-B (1) is able to obviate A $\beta$  nucleation and form spherical aggregates, considered to be the main neuroThe data presented here adds further support to our original hypothesis, that covalent modification of A $\beta$ -peptides by lipid aldehyde **1** is a key event that facilitates fibrillization. This is emphasized with peptide **2 f**, that has no free primary amines with which to form a Schiff base with aldehyde **1**, and whose aggregation is not initiated with atheronal-B (Figure 31).

However, the most significant result to come from this work is the clear observation that the fibrillization of Aβpeptides **2a–f** is only accelerated by atheronal-B (**1**), if the  $\varepsilon$ amino group of Lys16 is available for covalent modification. This observation is the most dramatic in the case of peptide **2b** (**K\*16**) in which the  $\varepsilon$ -amino group of Lys28 and the  $\alpha$ amino group of Asp1 are both available for adduction, but there is still no initiation in fibrillization by atheronal-B (Figure 3b and h).

In line with current thinking on how hydrophobic peptide mutations contribute to peptide fibrillization through burial of hydrophobic surface,<sup>[19,20]</sup> we had initially speculated that covalent modification of the  $\varepsilon$ -amino group of Lys16, Lys28 and the  $\alpha$ -amino group of Asp1 with the hydrophobic aldehyde **1** would be sufficient to trigger amyloidogenesis. The hydrophobic effect may still impact amyloidogenesis once aldehyde **1** is adducted to A $\beta$ , but what is clear is that this process is specific to Lys16. Increasing local hydrophobicity at Lys28 and Asp1 by adduction of atheronal-B is not sufficient to trigger fibrillization.

Lys 16 sits at the N-terminus of the central hydrophobic cluster (CHC) which has been suggested to be a cholesterol binding domain of A $\beta$  (Figure 1b).<sup>[21]</sup> The binding of cholesterol by A $\beta$  has been linked to a role of membrane stabilization.<sup>[22,23]</sup> Given that atheronal-B (1) and cholesterol share structural simile, it seems plausible that upon adduction to Lys 16 binding of the *seco*-sterol 1 in the CHC may occur. We investigated such a hypothesis by studying the effect of cholesterol on atheronal-B(1)-induced fibrillization of A $\beta$ (1–40) (2a) (Figure 4). Cholesterol exhibits a concentration-dependent reduction of the ability of atheronal 1 to induce fibrillization of A $\beta$ (1–40) 2a, with an EC<sub>50</sub> (effective concentration that reduces the maximum ThT-positive aggregates to 50% of the untreated) of ca. 30 µM. This is the first example of



**Figure 4.** Cholesterol inhibits aldehyde 1-induced A $\beta$ (1–40) fibrillization. ThT fluorescence of A $\beta$ (1–40) (**2a**) (100  $\mu$ M) in the presence (**a**) or absence (**b**) of 1 (100  $\mu$ M) and cholesterol (0–50  $\mu$ M) (PBS, pH 7.4 and 37 °C). Each point is the mean  $\pm$  SD of duplicate measurements.

## Communications

inhibition of atheronal-induced A $\beta$  aggregation by a molecule that does not trap the aldehyde of atheronal-B with a nucleophile.<sup>[4,8,16]</sup> Cholesterol could be impacting aldehydeinduced fibrillization of A $\beta$  by competing with atheronal-B (**1**) for the CHC domain or alternatively, by binding in the CHC domain cholesterol may block adduction of atheronal-B to Lys16. Further studies are ongoing to unravel this effect, but clearly there are molecular recognition events occurring between atheronal-B and A $\beta$  that go beyond Schiff-base formation with Lys16 and could well form the basis for the development of inhibitors as potential therapeutics for Alzheimer's disease.

In summary, we have discovered that cholesterol secosterol-1-induced aggregation of Aß involves a site-specific adduction of the aldehyde to the ε-amino group of Lys16, suggesting that Lys16 is a hot spot for atheronal-induced fibrillization of A $\beta$ . This process can be inhibited by molecules that compete for the CHC binding domain. Although in this report we have focused on the interaction between 1 and 2a, the implications are more wide reaching for protein misfolding and disease. We have previously shown that lipid aldehydes cause the misfolding of other diseaserelated proteins such as apoB-100<sup>[5]</sup> and  $\alpha$ -synuclein.<sup>[6]</sup> This study suggests that there may be specific hot spots on misfolding prone proteins at which molecular recognition events with specific lipid aldehydes may bind, and in such cases this process may be amenable to competition and inhibition by small molecules that may ultimately lead to new therapeutic targets.

Received: December 22, 2007 Revised: January 26, 2008 Published online: April 11, 2008

**Keywords:** alzheimer's disease  $\cdot$  amyloids  $\cdot$  lipid peroxidation  $\cdot$  methylation  $\cdot$  protein misfolding

[1] C. Haass, H. Steiner, Nat. Neurosci. 2001, 4, 859.

- [2] W. L. Klein, W. B. Stine, Jr., D. B. Teplow, Neurobiol. Aging 2004, 25, 569.
- [3] F. Chiti, C. M. Dobson, Annu. Rev. Biochem. 2006, 75, 333.
- [4] J. Bieschke, Q. Zhang, D. A. Bosco, R. A. Lerner, E. T. Powers, P. Wentworth, J. W. Kelly, Acc. Chem. Res. 2006, 39, 611.
- [5] P. Wentworth, Jr., J. Nieva, C. Takeuchi, R. Galve, A. D. Wentworth, R. B. Dilley, G. A. DeLaria, A. Saven, B. M. Babior, K. D. Janda, A. Eschenmoser, R. A. Lerner, *Science* 2003, 302, 1053.
- [6] D. A. Bosco, D. M. Fowler, Q. Zhang, J. Nieva, E. T. Powers, P. Wentworth, Jr., R. A. Lerner, J. W. Kelly, *Nat. Chem. Biol.* 2006, 2, 249.
- [7] C. Takeuchi, R. Galve, J. Nieva, D. P. Witter, A. D. Wentworth, R. P. Troseth, R. A. Lerner, P. Wentworth, *Biochemistry* 2006, 45, 7162.
- [8] Q. Zhang, E. T. Powers, J. Nieva, M. E. Huff, M. A. Dendle, J. Bieschke, C. G. Glabe, A. Eschenmoser, P. Wentworth, Jr., R. A. Lerner, J. W. Kelly, *Proc. Natl. Acad. Sci. USA* **2004**, *101*, 4752.
- [9] I. Casserly, E. J. Topol, *Lancet* 2004, *363*, 1139.
  [10] M. Schnolzer, P. Alewood, A. Jones, D. Alewood, S. B. Kent, *Int. J. Pept. Protein Res.* 1992, *40*, 180.
- [11] S. Hyun, H. J. Kim, J. N. Lee, K. H. Lee, Y. Lee, D. R. Ahn, K. Kim, S. Jeong, J. Yu, J. Am. Chem. Soc. 2007, 129, 4514.
- [12] H. Levine III, Protein Sci. 1993, 2, 404.
- [13] J. D. Harper, P. T. Lansbury, Jr., Annu. Rev. Biochem. 1997, 66, 385.
- [14] D. B. Teplow, Amyloid 1998, 5, 121.
- [15] W. B. Stine, Jr., K. N. Dahlgren, G. A. Krafft, M. J. LaDu, J. Biol. Chem. 2003, 278, 11612.
- [16] J. Bieschke, Q. Zhang, E. T. Powers, R. A. Lerner, J. W. Kelly, *Biochemistry* 2005, 44, 4977.
- [17] A. R. Hurshman, J. T. White, E. T. Powers, J. W. Kelly, *Bio-chemistry* 2004, 43, 7365.
- [18] H. Y. Shao, S. C. Jao, K. Ma, M. G. Zagorski, J. Mol. Biol. 1999, 285, 755.
- [19] G. Bitan, S. S. Vollers, D. B. Teplow, J. Biol. Chem. 2003, 278, 34882.
- [20] F. Chiti, M. Stefani, N. Taddei, G. Ramponi, C. M. Dobson, *Nature* 2003, 424, 805.
- [21] T. J. Nelson, D. L. Alkon, J. Biol. Chem. 2005, 280, 7377.
- [22] N. A. Avdulov, S. V. Chochina, U. Igbavboa, C. S. Warden, A. V. Vassiliev, W. G. Wood, *J. Neurochem.* **1997**, *69*, 1746.
- [23] Z.-X. Yao, V. Papadopoulos, FASEB J. 2002, 16, 1677.